Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression

2021 ◽  
pp. 33-54
Author(s):  
Maureen L. Drakes ◽  
Patrick J. Stiff
Keyword(s):  
Ovarian Cancer ◽  
Immune Suppression ◽  
Therapeutic Strategies

Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy

2019 ◽  
Vol 19 (6) ◽  
pp. 449-467
Author(s):  
Zhiquan Liang ◽  
Ziwen Lu ◽  
Yafei Zhang ◽  
Dongsheng Shang ◽  
Ruyan Li ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Cells ◽  
Receptor Binding ◽  
Cytoreductive Surgery ◽  
Therapeutic Strategies ◽  
Membrane Receptors ◽  
Ovarian Cancer Cells ◽  
Advanced Stage ◽  
Targeted Therapeutics ◽  
Cellular Processes

Ovarian cancer is a leading cause of death worldwide from gynecological malignancies, mainly because there are few early symptoms and the disease is generally diagnosed at an advanced stage. In addition, despite the effectiveness of cytoreductive surgery for ovarian cancer and the high response rates to chemotherapy, survival has improved little over the last 20 years. The management of patients with ovarian cancer also remains similar despite studies showing striking differences and heterogeneity among different subtypes. It is therefore clear that novel targeted therapeutics are urgently needed to improve clinical outcomes for ovarian cancer. To that end, several membrane receptors associated with pivotal cellular processes and often aberrantly overexpressed in ovarian cancer cells have emerged as potential targets for receptor-mediated therapeutic strategies including specific agents and multifunctional delivery systems based on ligand-receptor binding. This review focuses on the profiles and potentials of such strategies proposed for ovarian cancer treatment and imaging.

scholarly journals Novel Therapeutic Strategies for Ovarian Cancer Stem Cells

2020 ◽  
Vol 10 ◽  
Author(s):  
Nastassja Terraneo ◽  
Francis Jacob ◽  
Anna Dubrovska ◽  
Jürgen Grünberg
Keyword(s):  
Ovarian Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Therapeutic Strategies ◽  
Ovarian Cancer Stem Cells ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

scholarly journals Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies

Oncotarget ◽  
2016 ◽  
Vol 0 (0) ◽  
Author(s):  
Lara Paracchini ◽  
Laura Mannarino ◽  
Ilaria Craparotta ◽  
Chiara Romualdi ◽  
Robert Fruscio ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Therapeutic Strategies ◽  
Temporal Heterogeneity ◽  
Cancer Tumor ◽  
Tumor Biopsies

scholarly journals Therapeutic strategies in epithelial ovarian cancer

2012 ◽  
Vol 31 (1) ◽  
pp. 14 ◽  
Author(s):  
Ayako Kim ◽  
Yutaka Ueda ◽  
Tetsuji Naka ◽  
Takayuki Enomoto
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Therapeutic Strategies

Abstract B29: Cisplatin is pro-immunogenic and promotes intrinsic and reactive immune suppression in inflamed and noninflamed ovarian cancer mouse models

2018 ◽  
Author(s):  
Shannon Grabosch ◽  
Mirna Bulatovic ◽  
Feitianzhi Zeng ◽  
Tianzhou Ma ◽  
Lixin Zhang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Mouse Models ◽  
Immune Suppression

Heat Shock Protein Vaccine Therapy for Ovarian Cancer

2018 ◽  
Author(s):  
Hiroyuki Abe ◽  
Amane Sasada ◽  
Shigeki Tabata ◽  
Minako Abe
Keyword(s):  
Ovarian Cancer ◽  
Heat Shock ◽  
Heat Shock Protein ◽  
Immune Suppression ◽  
Poor Prognosis ◽  
Critical Role ◽  
Combination Immunotherapy ◽  
Protein Vaccine ◽  
Key Technologies ◽  
Method Of Production

Despite advances in chemotherapeutic regimens, ovarian cancer has a poor prognosis. Therefore important effective treatments are urgently needed. Many studies have reported that the immune system plays a critical role in disease progression and overall survival. One known effective immunotherapy is the dendritic cell (DC)-based vaccine pulsed with tumor-associated antigens. This chapter reports on a method of production of a novel DC-based vaccine. The key technologies are (a) monocyte collection without leukapheresis, (b) monocyte expansion, (c) production of dendritic cells, (d) multiple overlapping long peptides with heat shock protein 70, and (e) combination immunotherapy approach. The next generation of immunotherapy for ovarian cancer will be focused on combination approaches that simultaneously augment immunity while preventing local immune suppression. Possible combinations which might be useful to help patients with ovarian cancer are summarized in this chapter.

scholarly journals Therapeutic Strategies in Ovarian Cancer

10.5772/39132 ◽  
2012 ◽  
Author(s):  
Dan Ancua ◽  
Octavian Neagoe ◽  
Rzvan Ilina ◽  
Adrian Carabineanu ◽  
Corina erban ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Therapeutic Strategies

scholarly journals Regulatory T Cells in Human Ovarian Cancer

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Dong-Jun Peng ◽  
Rebecca Liu ◽  
Weiping Zou
Keyword(s):  
Ovarian Cancer ◽  
T Cells ◽  
Immune Suppression ◽  
Immune Cells ◽  
Clinical Settings ◽  
Human Ovarian Cancer ◽  
Cancer Microenvironment ◽  
Cellular Mechanisms ◽  
And Function ◽  
Antigen Presenting

Multiple layers of suppressive components including regulatory T (TReg) cells, suppressive antigen-presenting cells, and inhibitory cytokines form suppressive networks in the ovarian cancer microenvironment. It has been demonstrated that as a major suppressive element, TRegcells infiltrate tumor, interact with several types of immune cells, and mediate immune suppression through different molecular and cellular mechanisms. In this paper, we focus on human ovarian cancer and will discuss the nature of TRegcells including their subsets, trafficking, expansion, and function. We will briefly review the development of manipulation of TRegcells in preclinical and clinical settings.

Sign in / Sign up

Export Citation Format

Share Document